Abstract
Background and purpose:
PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer 89Zr-cetuximab and to assess tumour uptake.
Methods:
Two dose schedules were used; two consecutive doses of 60 MBq 89Zr-cetuximab or a single dose of 120 MBq, both preceded by 400 mg/m2 of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.
Results:
Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of 89Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR) > 1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals > 5 days after injection.
Conclusions:
Both presented 89Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60 MBq, with a minimum time interval for scanning of 6 days.
Original language | English |
---|---|
Pages (from-to) | 267-273 |
Number of pages | 7 |
Journal | Radiotherapy and Oncology |
Volume | 122 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2017 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2016 Elsevier Ireland Ltd